Eterna Therapeutics Inc., a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, announced the appointment of Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung will work with Eterna’s senior leadership and the Board of Directors to develop and advance the Company’s corporate strategy. Ms. Yung will also oversee the company’s legal activities, including licensing and intellectual property matters.
“Megan is an experienced biotech strategist with a proven track record of building value for companies through high-value strategic transactions and we are thrilled to welcome her to Eterna’s leadership team,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. “Her deep experience operating at the intersection of science, corporate strategy and intellectual property will benefit Eterna, our current and potential partners, and our shareholders through her focus on advancing the company’s business strategies, as we continue supporting the development of next-generation mRNA-based therapeutic products.”
Ms. Yung added, “I look forward to working closely with the Eterna leadership team and Board to advance the company’s strategy while maintaining capital efficiency, as Eterna enters a new chapter following its recent acquisition of Exacis Biotherapeutics. RNA-based therapeutics have continued to garner significant scientific and investor interest and Eterna is well-primed to create value through new strategic collaborations.”
Ms. Yung holds a J.D. from The George Washington University Law School and joins Eterna from SQZ Biotechnologies, where she served as Deputy General Counsel and Vice President, Head of Intellectual Property, and helped oversee matters of intellectual property, regulatory compliance, public company reporting, business development activities and negotiations, and government affairs. Prior to SQZ, Ms. Yung held in-house counsel positions where she served as a key member of the deal teams involving strategic bet-the-company, venture capital, and private equity financing deals, and as chief counsel on all litigation, including intellectual property, employment matters, and class action law suits. These successful activities built on the expertise she cultivated as an intellectual property attorney at Quinn Emanuel Urquhart & Sullivan, Mintz Levin Cohn Ferris Glovksy and Popeo, and Foley & Lardner, where she represented and advised biotech and pharmaceutical companies in patent litigation, prosecution, and IP strategy.